SUPERNUS PHARMACEUTICALS, INC. - 8-K Filing

Supernus Pharmaceuticals requests Nasdaq delisting and SEC deregistration following completion of merger on November 2, 2026. (Items: 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing)

SEC EDGAR ·

Tickers: $SUPN

Read the full article at SEC EDGAR

More Regulatory news